Linagliptin/metformin

Drug Profile

Linagliptin/metformin

Alternative Names: BI 10773/linagliptin FDC (high dose) - Boehringer Ingelheim; Jentadueto; Jentadueto XR; JentaDuo; linagliptin and metformin hydrochloride extended-release; Linagliptin/metformin FDC; Metformin/linagliptin; Trajenta Duo

Latest Information Update: 30 Dec 2016

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Eli Lilly
  • Class Alkynes; Antihyperglycaemics; Biguanides; Insulin sensitisers; Piperidines; Purines; Quinazolines; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; CD26 antigen inhibitors; Gluconeogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 15 Dec 2016 Committee for Medicinal Products for Human Use (CHMP) of EMA adopts a positive opinion recommending approval of linagliptin/metformin for extension to an existing indication of Type-2 diabetes mellitus
  • 31 May 2016 Linagliptin/metformin has a boxed warning for lactic acidosis
  • 27 May 2016 US FDA approves linagliptin/metformin (extended release formulation) for Type-2 diabetes mellitus in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top